R
Rafael Alfonso-Cristancho
Researcher at GlaxoSmithKline
Publications - 87
Citations - 23192
Rafael Alfonso-Cristancho is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 25, co-authored 54 publications receiving 19735 citations. Previous affiliations of Rafael Alfonso-Cristancho include University of Washington.
Papers
More filters
Journal ArticleDOI
Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A
Mark Liu,Diego Bagnasco,Andrea Matucci,Charles Pilette,Robert Price,Aoife C. Maxwell,Rafael Alfonso-Cristancho,R.W. Jakes,Jason Lee,Amarjit Cheema,Peter H. Howarth +10 more
TL;DR: Gastroesophageal reflux disease (GERD) and anxiety/depression are common comorbidities in patients with severe eosinophilic asthma; they add to disease burden and may influence treatment responses as mentioned in this paper .
Journal ArticleDOI
Empirical Estimation Of Statistical Power And Minimum Number Of Studies Needed For A Network Meta-Analysis
Daniel Parks,K. Lee,O. Dabbous,X. Lin,Sarah Cockle,Richard H. Stanford,Rafael Alfonso-Cristancho +6 more
TL;DR: This work simulates the interaction of the fixed effect model or the random effect model for handling betweenstudy variation for the Bayesian method and records the output from indirect comparison.
Proceedings ArticleDOI
Mepolizumab effectiveness in severe asthma supported by federated analysis of European SHARP data
Johannes A. Kroes,Rafael Alfonso-Cristancho,Aruna T. Bansal,E. Berret,Kristina Bieksiene,Aline Bourdin,Luisa Brussino,Diana Sofia de Melo Canhoto,Cristina Cardini,G Celik,Zsuzsanna Csoma,Babro Dahlen,Ebru Damadoğlu,Katrien Eger,L Gauquelin,Bilun Gemicioglu,Ozlem Goksel,Sophie Graff,Enrico Heffler,H. Bas Hofstee,Peter H. Howarth,R.W. Jakes,Fabienne Jaun,Virginija Kalinauskaite-Zukauske,Peter Kopač,Namhee Kwon,Cláudia Chaves Loureiro,V. Lozoya García,Matthew Masoli,M. Paula Rezelj,Luis Pérez de Llano,Sanja Popović-Grle,David Ramos-Barbón,Ana Sá Sousa,Konstantinos Samitas,Florence Schleich,Concetta Sirena,Sabina Skrgat,Eleftherios Zervas,G. Zichnalis,Elisabeth H. Bel,Jacob K. Sont,Simone Hashimoto,Anneke ten Brinke +43 more
TL;DR: In this paper , the authors used federated analysis to evaluate the effectiveness of mepolizumab on frequent (≥2/yr) exacerbations in patients with severe asthma.
Journal ArticleDOI
Real World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A
Frances Lee,Mark Liu,Diego Bagnasco,Andrea Matucci,Charles Pilette,Robert Price,Rafael Alfonso-Cristancho,R.W. Jakes,Peter H. Howarth +8 more
TL;DR: In clinical trials, mepolizumab reduced clinically significant exacerbations (CSEs) and maintenance oral corticosteroid (mOCS) use in patients with severe eosinophilic asthma (SEA) as mentioned in this paper .
Journal ArticleDOI
The sustained ocs-sparing effect of mepolizumab: results from the real-world realiti-a study at 2 years
S. Pollard,J. Offenberger,Frank Lee,M. Liu,Rafael Alfonso-Cristancho,RG Price,Peter H. Howarth +6 more
TL;DR: RealITI-A as mentioned in this paper was a 2-year international, prospective study, enrolling patients with asthma, newly prescribed mepolizumab 100 mg subcutaneously at physician's discretion.